<DOC>
	<DOCNO>NCT00556049</DOCNO>
	<brief_summary>The purpose research study determine combination sunitinib gemcitabine effective treating patient metastatic renal cell carcinoma . The safety combination also study . Sunitinib approve FDA treatment renal cell carcinoma . However , patient ' cancer respond treatment stop respond initially respond . Gemcitabine chemotherapy drug approve FDA treatment pancreatic cancer several cancer . It approve treatment renal cell carcinoma . Previous research suggest combine gemcitabine sunitinib may effectiveness treat metastatic renal cell carcinoma .</brief_summary>
	<brief_title>Combination Sunitinib Gemcitabine Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>- Participants receive study treatment outpatient . Study treatment give 3-week cycle . - Sunitinib take orally per day first two week ( day 1-14 ) treatment cycle . - Gemcitabine give intravenously study clinic day 1 8 treatment cycle . - Before receive sunitinib gemcitabine day 1 cycle follow perform : physical exam , performance status assessment blood work . Before receive gemcitabine day 8 follow perform : physical exam , performance status assessment blood work . Every 3 cycle CT scan perform measure tumor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically prove metastatic renal cell carcinoma sarcomatoid histology poorrisk feature define 3 follow characteristic : PS &gt; 1 , high serum lactate dehydrogenase low hemoglobin high `` correct '' serum calcium 2 site metastatic disease time initial diagnosis evidence metastatic disease 12 month less Evidence unidimensional measurable disease base RECIST criterion , least 1 measurable lesion Male female , 18 year age old ECOG performance status 02 Patients brain metastasis include treated 4 week prior enrollment whole brain radiation effect treatment resolve Resolution acute toxic effect prior therapy , radiotherapy surgical procedure NCI CTCAE version 3.0 grade 1 less Laboratory value outline protocol 2 week must elapse time major surgery radiation therapy prior day registration No anticipate need major surgical procedure course study Prior treatment sunitinib gemcitabine More one prior systemic therapy kind renal cell carcinoma Uncontrolled high blood pressure Any prior history hypertensive crisis hypertensive encephalopathy Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , cerebrovascular accident transient ischemic attack , symptomatic congestive heart failure Ejection fraction &lt; 30 % Preexisting thyroid abnormality thyroid function maintain normal range medication NCT CTCAE grade 3 high hemorrhage within 4 week start treatment Significant vascular disease Current grade 3 high cardiac dysrhythmia QT prolongation Concurrent use proarrhythmic medication include terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide Pregnancy breastfeed inadequate contraception Evidence bleed diathesis coagulopathy Serious , nonhealing wound , ulcer bone fracture Psychiatric illness/social situation would limit compliance study requirement Previous diagnosis concurrent malignancy require active systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>mRCC</keyword>
	<keyword>sunitinib</keyword>
	<keyword>gemcitabine</keyword>
</DOC>